Finance

Committee Report Targets FDA, Biogen on Alzheimer's Treatment


A congressional report finds the FDA’s approval process for Biogen’s Alzheimer’s treatment was ‘rife with irregularities’ that included ‘atypical …

Read more

Show More

Related Articles

Back to top button